Correlations between Total Antioxidant Capacity and 8-Hydroxydeoxyguanosine with Carotid-Femoral Pulse Wave Velocity in Chronic Kidney Disease

Mochammad Yusuf Alsagaff, Budi Susetyo Pikir, Mochammad Thaha Thaha, Hendri Susilo


BACKGROUND: Chronic kidney disease (CKD) is often associated with an increased risk of cardiovascular disease. Cardiovascular disease in CKD can be affected by oxidative stress and inflammation. The oxidative stress can affect arterial stiffness, especially in patients with CKD, which will increase the risk of cardiovascular disease. This study aimed to explain the correlation between total antioxidant capacity (TAC) and 8-hydroxydeoxyguanosine (8-OHdG) with carotid-femoral pulse wave velocity (cf-PWV) in patients with CKD.

METHODS: Forty-three CKD patients was included in this cross-sectional study. TAC was measured from serum samples by colorimetric method and 8-OHDG was measured from urine by enzyme-linked immunoassay method. cf-PWV was measured by Doppler ultrasound as a diagnostic tool for arterial stiffness.

RESULTS: Significant correlations were found between age, estimated glomerular filtration rate (e-GFR), Hemoglobin A1C (HbA1C), serum creatinine, cystatin-C, and severity of CKD with urinary 8-OHdG levels. Serum creatinine, cystatin-C, severity of CKD, age, high-density lipoprotein (HDL), e-GFR, and HbA1C also had significant correlations with serum TAC levels. Other significant correlations between e-GFR, HbA1C, serum creatinine, cystatin-C, and severity of CKD with cf-PWV were also obtained. A significant negative correlation was obtained between serum TAC and cf-PWV with moderate levels of correlation coefficient (r=-0.504).

CONCLUSION: There was a negative correlation between TAC and cf-PWV, but there was no significant correlation between 8-OHdG and cf-PWV in patients with CKD.

KEYWORDS: chronic kidney disease, total antioxidant capacity, 8-hydroxydeoxyguanosine, carotid-femoral pulse wave velocity

Full Text:



Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375: 2073-81, CrossRef.

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016; 11: e0158765, CrossRef.

Whitman IR, Feldman HI, Deo R. CKD and sudden cardiac death: Epidemiology, mechanisms, and therapeutic approaches. J Am Soc Nephrol. 2012; 23: 1929-39, CrossRef.

Wright J, Hutchison A. Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag. 2009; 5: 713-22, CrossRef.

Cachofeiro V, Goicochea M, De Vinuesa SG, Oubĩa P, Lahera V, Lũo J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int. 2008; 74: S4-S9, CrossRef.

Thaha M, Kadariswantiningsih IN, Empitu MA. Association of high blood pressure with elevated oxidative stress, inflammatory marker and albuminuria in chronic kidney disease patients. J Med. 2019; 20: 12-8, CrossRef.

Daenen K, Andries A, Mekahli D, Van Schepdael A, Jouret F, Bammens B. Oxidative stress in chronic kidney disease. Pediatr Nephrol. 2019; 34: 975-991, CrossRef.

Fraga CG, Oteiza PI, Galleano M. In vitro measurements and interpretation of total antioxidant capacity. Biochim Biophys Acta. 2014; 1840: 931-4, CrossRef.

Sova H, Jukkola-Vuorinen A, Puistola U, Kauppila S, Karihtala P. 8-Hydroxydeoxyguanosine: A new potential independent prognostic factor in breast cancer. Br J Cancer. 2010; 102: 1018-23, CrossRef.

Silva IVG, De Figueiredo RC, Rios DRA. Effect of different classes of antihypertensive drugs on endothelial function and inflammation. Int J Mol Sci. 2019; 20: 5-9, CrossRef.

Ismaeel A, Brumberg RS, Kirk JS, Papoutsi E, Farmer PJ, Bohannon WT, et al. Oxidative stress and arterial dysfunction in peripheral artery disease. Antioxidants. 2018; 7: 1-16, CrossRef.

Zanoli L, Rastelli S, Inserra G, Castellino P. Arterial structure and function in inflammatory bowel disease. World J Gastroenterol. 2015; 21: 11304-11, CrossRef.

Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, et al. Aortic pulse wave velocity improves cardiovascular event prediction: An individual participant metaanalysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014; 63: 636-46, CrossRef.

Marrocco I, Altieri F, Peluso I. Measurement and clinical significance of biomarkers of oxidative stress in humans. Oxid Med Cell Longev. 2017; 2017: 1-32, CrossRef.

Ho E, Karimi Galougahi K, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol. 2013; 1: 483-91, CrossRef.

Valdivielso JM, Jacobs-Cachá C, Soler MJ. Sex hormones and their influence on chronic kidney disease. Curr Opin Nephrol Hypertens. 2019; 28: 1-9, CrossRef.

Duru OK, Li S, Jurkovitz C, Bakris G, Brown W, Chen SC, et al. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008; 51: 192-8, CrossRef.

Gómez-Marcos MÁ, Recio-Rodríguez JI, Gómez-Sánchez L, Agudo- Conde C, Rodríguez-Sanchez E, Maderuelo-Fernandez JA, et al. Gender differences in the progression of target organ damage in patients with increased insulin resistance: The LOD-DIABETES study. Cardiovasc Diabetol. 2015; 14: 132, CrossRef.

Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. J Am Med Assoc. 2007; 298: 2038-47, CrossRef.

Prakash S, O’Hare AM. Interaction of aging and chronic kidney disease. Semin Nephrol. 2009; 29: 497-503, CrossRef.

Bergesio F, Monzani G, Ciuti R, Pinzani P, Fiaschi N, Priami F, et al. Total antioxidant capacity (TAC): is it an effective method to evaluate the oxidative stress in uraemia? J Biolumin Chemilumin. 1998; 13: 315-9, CrossRef.

Fabbrini E, Serafini M, Colic Baric I, Hazen SL, Klein S. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes. 2014; 63: 976-81, CrossRef.

Muralidharan N, Bhat T, N SK. A study on effect of ageing on the levels of total antioxidant and lipid peroxidation. Int J Contemp Med Res. 2017; 4: 8-10, article.

Ganjifrockwala FA, Joseph JT, George G. Decreased total antioxidant levels and increased oxidative stress in South African type 2 diabetes mellitus patients. J Endocrinol Metab Diabetes South Africa. 2017; 22: 21-5, CrossRef.

Dong QY, Cui Y, Chen L, Song J, Sun L. Urinary 8-hydroxydeoxyguanosine levels in diabetic retinopathy patients. Eur J Ophthalmol. 2008; 18: 94-8, CrossRef.

Syslová K, Böhmová A, Mikoška M, Kuzma M, Pelclová D, Kačer P. Multimarker screening of oxidative stress in aging. Oxid Med Cell Longev. 2014; 2014: 562860, CrossRef.

Montesa MJP, Rico MAG, Salguero MAS, Maicas IT, Muñoz MCT, Tormo GS, et al. Study of oxidative stress in advanced kidney disease. Nefrologia. 2009; 29: 464-73, CrossRef.

Waziri B, Duarte R, Naicker S. Chronic kidney disease–mineral and bone disorder (CKD-MBD): current perspectives. Int J Nephrol Renov Dis. 2019; 12: 263-76, CrossRef.

Vikrant S, Parashar A. Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India. Indian J Endocrinol Metab. 2016; 20: 460-7, CrossRef.

Lioufas N, Hawley CM, Cameron JD, Toussaint ND. Chronic kidney disease and pulse wave velocity: A narrative review. Int J Hypertens. 2019; 2019: 9189362, CrossRef.

Cao J, Wang HY. Association between total antioxidant status and atherosclerosis in elderly patients with essential hypertension. Chinese J Cardiol. 2013; 41: 857-61, article.

Jürgenson J, Serg M, Kampus P, Kals J, Zagura M, Viru M, et al. Oxidative stress parameters and its associations with arterial stiffness in competitive powerlifting athletes after 12-week supervised strength training. J strength Cond Res. 2019; 33: 1816-22, CrossRef.

Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitric oxide and atherosclerosis: An update. Nitric Oxide - Biology and Chemistry. 2006; 15: 265-79, CrossRef.

Dalfino G, Simone S, Porreca S, Cosola C, Balestra C, Manno C, et al. Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. Atherosclerosis. 2010; 211: 418-23, CrossRef.

Kotani K, Yamada T. Association between urinary 8-OHdG and pulse wave velocity in hypertensive patients with type 2 diabetes mellitus. Singapore Med J. 2014; 55: 202-8, CrossRef.

Chade AR, Lerman A, Lerman LO. Kidney in early atherosclerosis. Hypertension. 2005; 45: 1042-9, CrossRef.

Duni A, Liakopoulos V, Roumeliotis S, Peschos D, Dounousi E. Oxidative stress in the pathogenesis and evolution of chronic kidney disease: Untangling ariadne’s thread. Int J Mol Sci. 2019; 20: 3711, CrossRef.

Ogunleye A, Akinbodewa AA, Adejumo OA, Oluwafemi TT, Akinfaderin DA. Changes in antioxidant status associated with haemodialysis in chronic kidney disease. Ghana Med J. 2018; 52: 29-33, CrossRef.

Miao R, Wu L, Ni P, Zeng Y, Chen Z. The comorbidity of increased arterial stiffness and microalbuminuria in a survey of middle-aged adults in China. BMC Cardiovasc Disord. 2018; 18: 83, CrossRef.

Huh JY, Son DJ, Lee YJ, Lee JH, Kim BY, Lee HM, et al. 8-Hydroxy-2-deoxyguanosine prevents plaque formation and inhibits vascular smooth muscle cell activation through Rac1 inactivation. Free Radic Biol Med. 2012; 53: 109-21, CrossRef.


Indexed by:






The Prodia Education and Research Institute